Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | PDE2A | O00408 | 7/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12583791 | 0.97 | DRD2 (0.38) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL10167172 | 0.85 | DRD2 (0.37) | AKT1AKT2DRD2RORC | |
| SCHEMBL10226697 | 0.85 | DRD2 (0.35) | AKT1AKT2DRD2RORC | |
| SCHEMBL14161397 | 0.83 | AKT1 (0.42) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL13047444 | 0.82 | AKT1 (0.41) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL12134686 | 0.82 | AKT1 (0.41) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL10167156 | 0.82 | DRD2 (0.51) | AKT1AKT2DRD2CNR1CNR2 | |
| SCHEMBL360875 | 0.82 | AKT1 (0.45) | AKT1AKT2DRD2PDE2ARORC | |
| SCHEMBL17040898 | 0.82 | SSTR4 (0.47) | AKT1AKT2CNR1CNR2SSTR4 | |
| SCHEMBL10226580 | 0.82 | DRD2 (0.33) | AKT1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691825-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130287763-A1 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-10-31 | — | — | US | disclosed |
| US-8536193-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8288407-B2 | Substituted naphthyridine compounds as inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161317-A1 | Inhibitors of Akt activity | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885DRD2 3852/4885 |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885DRD2 3852/4885 |
| US-20130287763-A1 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | IGF1R, IGFBP1, IGFBP2 | AKT1 65/4885AKT2 28/4885DRD2 4750/4885 |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT1S1, AKT1 | AKT1 3/4885AKT2 5/4885DRD2 3225/4885 |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885DRD2 3852/4885 |
| US-20120077810-A1 | Inhibitors Of AKT Activity | PIK3CA, PIK3CD, PIK3CB | AKT1 11/4885AKT2 7/4885DRD2 4382/4885 |
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | AKT1 9/4885AKT2 5/4885DRD2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.